1. Home
  2. CTRM vs MRKR Comparison

CTRM vs MRKR Comparison

Compare CTRM & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

N/A

Current Price

$2.20

Market Cap

21.2M

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

N/A

Current Price

$1.46

Market Cap

23.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTRM
MRKR
Founded
2016
N/A
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
23.0M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
CTRM
MRKR
Price
$2.20
$1.46
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$11.25
AVG Volume (30 Days)
55.1K
145.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$0.81
52 Week High
$2.67
$4.07

Technical Indicators

Market Signals
Indicator
CTRM
MRKR
Relative Strength Index (RSI) 51.61 48.94
Support Level $2.04 $1.37
Resistance Level $2.43 $1.69
Average True Range (ATR) 0.10 0.12
MACD -0.01 -0.00
Stochastic Oscillator 34.48 50.00

Price Performance

Historical Comparison
CTRM
MRKR

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: